Ultragenyx Takes On Rare Childhood Disease With In-licensing Deal

Rare disease company Ultragenyx has in-licensed the North American rights to a treatment for fatty-acid oxidation disorder, adding its third clinical-stage drug to its ultra-rare disease pipeline.